StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX)

Investment analysts at StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a research note issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

DURECT Stock Performance

Shares of NASDAQ:DRRX opened at $0.80 on Wednesday. The business has a fifty day moving average of $0.80 and a 200-day moving average of $1.04. DURECT has a twelve month low of $0.70 and a twelve month high of $1.88. The firm has a market cap of $24.83 million, a PE ratio of -1.31 and a beta of 0.91.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Richmond Brothers Inc. boosted its position in DURECT by 12.2% in the 4th quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after buying an additional 138,920 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of DURECT by 266.0% during the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 28,486 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in DURECT by 4.8% in the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 14,658 shares during the last quarter. Institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.